Pathological measurement and staging of residual breast cancer after neoadjuvant chemotherapy
Histopathology · 2023-09 · 83 (3) · 453-464
DOI: 10.1111/his.14966 ↗Kurz gefasst
Fachartikel in der Zeitschrift Histopathology, online erschienen am 31.05.2023. Verfasst von Dawn Harter und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Aims
The 8th Edition of the American Joint Committee on Cancer Staging System (yAJCC) excludes treatment‐related fibrosis from the measurement of residual tumour after neoadjuvant chemotherapy (NAC) for breast cancer. The impact of the 8th Ed. yAJCC on post‐NAC pathologic staging was examined in 188 breast cancer specimens from 183 patients with measurable residual tumour.
Methods
Tumour size, ypT, and ypN categories were reassessed with the current yACC criteria and compared to the original pathology reports. Histological patterns of response in the breast were categorised as concentric or scattered.
Results
The reassessed breast tumour size or ypT category differed from the original report in 101 (53.7%) cases. Changes in the ypT and/or ypN category resulted in downstaging of 45/185 (24.3%). A smaller reassessed tumour size or lower ypT category occurred more often in hormone receptor‐positive/HER2‐negative (HR+/HER2−) (68.3%) and HER2‐positive (HER2+) tumours (74.0%) than triple‐negative breast cancer (TNBC) (37.5%) ( P < 0.001). A scattered pattern of response was more frequent in HR+/HER2− (54.9%) and HER2+ (66.0%) tumours than TNBC (35.7%) ( P = 0.006). Changes in size, ypT, or multifocality based on the 8th Ed. yAJCC criteria were more frequent in tumours with a scattered pattern of response ( P < 0.001).
Conclusion
Strict adherence to yAJCC criteria for measurement of the residual breast tumour after NAC resulted in smaller tumour size, lower ypT category, lower yAJCC stage, and more frequent classification of residual tumour as multifocal. Downstaging based on 8th Ed. yAJCC criteria was associated with tumour subtype and histological pattern of response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
ORCID-Profile: Benjamin C Calhoun
Förderung
- NCI NIH HHS
Zitieren
APA
Harter, D., O'Connor, S. M., Hertel, J. D., & Calhoun, B. C. (2023). Pathological measurement and staging of residual breast cancer after neoadjuvant chemotherapy. Histopathology, 83(3), 453-464. https://doi.org/10.1111/his.14966
Vancouver
Harter D, O'Connor SM, Hertel JD, Calhoun BC. Pathological measurement and staging of residual breast cancer after neoadjuvant chemotherapy. Histopathology. 2023;83(3):453-464. doi:10.1111/his.14966
BibTeX
@article{Harter2023,
author = {Harter, Dawn and O'Connor, Siobhan M and Hertel, Johann D and Calhoun, Benjamin C},
title = {Pathological measurement and staging of residual breast cancer after neoadjuvant chemotherapy},
journal = {Histopathology},
year = {2023},
volume = {83},
number = {3},
pages = {453--464},
doi = {10.1111/his.14966}
}
EUVIMED